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Abstract 
Background: The prevalence of e-cigarettes and NRT use is increasing among general 
population in recent years. With the shifting in HIV-infection paradigm, describing the 
prevalence and pattern among men with high risk of HIV infection is important in 
chronic disease prevention and improving their life expectancy and quality.  
Objective: The aims of this study were 1) to provide a profile of current smoking, e-
cigarettes use and NRT use; 2) to identify risk factors associated with initiation of e-
cigarettes and NRT use among men with high risk of HIV infection. 
Design: A longitudinal study based on The Multicenter AIDS Cohort Study (MACS). A 
total of 2285 men were included with follow-ups starting from June 2015.  
Results: The prevalence of current smokers was constant from 2015 to 2017. Men 
without HIV had a similar prevalence as the general US adult men (16.7%-17.5%), at 
between 13.5% and 16.1%. Men with HIV had a higher prevalence at between 23.0% and 
26.1%. The prevalence of e-cigarettes (ranged between 5.2% to 9.3% for HIV infected 
men and between 3.1% and 5.7% for uninfected men) and NRT use (ranged between 
5.0% and 8.2% for infected men and between 3.5% and 4.6% for uninfected men.) did 
not differ by HIV status. The prevalence of e-cigarettes use was about 20% in current 
smokers, 4% in former smokers, and 0.3% for non-smokers. The prevalence of NRT use 
was about 12% in current smokers and about 3% in former smokers. Ever e-cigarettes 
and NRT users had a higher cumulative pack-year compared to never users. After 
adjusting for age, race, Hispanic ethnicity, education level, serostatus, detectable viral 
load, CD4 count and cumulative pack-years, the cumulative incidence risk (RR) ratio of 
e-cigarettes use was 0.98 (95% CI, 0.97-0.99) for one year increase in age; 1.46 (95% CI, 
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1.01-2.10) for high school level education compared to 4 years’ college and above, 1.55 
(95% CI, 1.03-2.35) for less than high school education compared to 4 years’ college and 
above, 1.09 (95% CI, 0.98-1.23) for HIV infection, and 1.02 (95% CI, 0.99-1.04) for 50% 
increase in cumulative pack-years. The cumulative incidence risk ratio of NRT use is 
0.95(95% CI, 0.95-0.97) for one-year increase in age, 1.32 (95%CI, 1.00-1.73) for being 
back, 1.48 (95% CI, 1.02-2.15) for high school level education compared to 4 years’ 
college and above, 1.31(95% CI, 0.99-1.72) and 1.10 (95% CI, 1.07-1.14) for 50% 
increase in cumulative pack-years.  
Conclusion: The prevalence of current smoking was higher for men with HIV than men 
without. E-cigarettes and NRT use was mostly common among current smokers, the 
prevalence did not differ by HIV status. E-cigarettes and NRT users had a longer 
cumulative pack-years compared to never users. Risk factors associated with e-cigarettes 
and NRT use included younger age, lower education level, HIV infection and longer 
cumulative pack-years. Black race is associated with NRT use. 
 
Primary reader: Derek Ng, PhD 
Secondary reader: Keri Althoff, PhD 
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Background 
The overall prevalence of cigarette smoking in the United States was about 15.1% in 2015 
and 15.5% in 2016 among adults (Jamal, 2018; Phillips, 2017). Adult men had a higher 
prevalence than women, the prevalence was 16.7% (95% CI, 15.9–17.6%) and 17.5% (95% 
CI, 16.6–18.5%) among males in 2015 and 2016; while for females was 13.6% (95% CI, 
12.9–14.3%) and 13.5% (95% CI, 12.8–14.3%) (Jamal, 2018; Phillips, 2017). 
 
Many studies have demonstrated that smoking causes many health conditions, including 
lung cancer, heart attacks, stroke, and chronic obstructive pulmonary disease (COPD). 
Tobacco use is therefore considered to be the biggest single cause of preventable death 
worldwide (Organization & Control, 2008). With the introduction of effective treatment 
including ART and HAART, the life expectancy of HIV-infected individuals is 
approaching the uninfected individuals. This shift in HIV infection paradigm makes it 
necessary to pay more attention to smoking cession among the infected individuals to 
prevent chronic diseases and to increase their life expectancy and quality (Althoff, 2016).  
 
E-cigarettes is a novel electronic nicotine delivery device that mimics traditional cigarette 
smoking through heating liquid that usually contains nicotine. They are often used as a 
substitute for cigarettes among those trying to quit smoking or as a novel nicotine delivery 
system among those without a history of cigarettes smoking. In the U.S. general population, 
the prevalence of e-cigarettes smoking was 4.3%(95% CI, 3.9-4.8%) (Phillips, 2017) in the 
US adult men in 2015, and 4.0%(95% CI, 3.6–4.3%) in 2013-2014 (Hu, 2016). Among the 
adults, the prevalence of e-cigarettes use was highest among current smokers, and much 
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lower among former and never smokers (Carroll Chapman & Wu, 2014). However, studies 
have shown that the usage pattern was different among adolescents. There was a notable 
portion of adolescent users started smoking with e-cigarettes instead of tradition cigarettes 
(Arrazola et al., 2015). Among adults, e-cigarettes were mostly used as a substitute for 
cigarettes smoking and the users may not always intend to quit smoking (Carroll Chapman 
& Wu, 2014). Risk factors for e-cigarettes use often varies across different populations, 
commonly identified indicators including race(Camenga et al., 2014), sociodemographic 
characteristics (Rutten et al., 2015), currently smoking(Wang, Wang, Cao, Wang, & Hu, 
2016), intention to quit smoking, and reliance on nicotine(Ramo, Young-Wolff, & 
Prochaska, 2015).  
 
E-cigarettes were introduce into the US market in 2007, and the use has been increasing 
since then(Chen, 2013). They are often perceived to be less harmful since the quantity of 
harmful compounds and heavy metals produced by e-cigarettes is lower than those from 
traditional cigarettes. Although e-cigarettes are considered to be less addictive, the risk of 
nicotine addiction and renormalization of smoking behaviors remains  (McMillen, Gottlieb, 
Shaefer, Winickoff, & Klein, 2015). Moreover, Bullen’s study have revealed that e-
cigarettes are very effective in helping quit smoking (Bullen et al., 2013). There was a 
review study on the prevalence in different age groups showing that the prevalence and use 
patterns varied among difference sub-populations. Current studies are mostly conducted 
among general population. In order to have a better understanding of the profile of e-
cigarettes use, it necessary to describe the e-cigarette use in a representative population of 
older men who have sex with men (MSM).  
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Nicotine replacement therapy (NRT) is most commonly used as a smoking cessation 
assistance to overcome highly nicotine dependent smokers’ withdraw feelings and cigarette 
cravings. Also it could be used as a way to reduce the amount of cigarette smoking. NRT 
provides a small amount of nicotine to reduce the urge to smoke. The types of NRT varies 
from patches, gum, lozenges, inhalers and nasal sprays. Among US male smokers trying 
to quit in 2015, 27.0% (95% CI, 24.0–30.0%) of them used medication as a cessation 
assistance (Babb, 2017). A British study published in 2014 showed the highest prevalence 
of 34.8% of NRT use among smokers quitted in recent 3 months; 11.8% among current 
smokers, and 7.8% among smokers who quitted more than 3 months ago (Shahab, Beard, 
Brown, & West, 2014). A Canadian population based survey published in 2014 reveals the 
prevalence of NRT use among current smokers was about 27% (Zhang, Cohen, Bondy, & 
Selby, 2015). A study based on US adult current smokers with a quit attempt showed risk 
factors associated with the NRT use, including older age, male, higher education, higher 
smoking intensity, and nicotine dependence. (Shiffman, 2005). 
 
NRT is proved to be effective in increasing the chance of success cessation by 50%-70% 
under standard use (Stead et al., 2012). The utilization of NRT increased recently in the 
general population. With a limited number of studies, the pattern of NRT use among MSM 
population remains unclear. An accurate description would be helpful in regulating and 
promoting the NRT use in order to support smoke cessation and prevent chronic diseases 
in this sub-population. 
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Compared with the general population, men at high risk of HIV infection are more likely 
to have substance abuse and addiction issues (Tetrault, Fiellin, & Sullivan, 2010). This 
might affect their smoking behaviors as well. There were evidence showing that men who 
have sex men had a higher prevalence of e-cigarettes usage (Gerend, Newcomb, & 
Mustanski, 2017). Study also suggested that poly-tobacco use was slightly higher among 
people with HIV than the general population (Pacek, Sweitzer, & McClernon, 2016). There 
are limited studies examining factors that might be associated with e-cigarettes or NRT use 
among men at high risk of HIV infection.  
 
The Multicenter AIDS Cohort Study (MACS) is a comprehensive longitudinal study of 
nearly 30 years of follow-up on almost 7000 men who are at high risk HIV infection. This 
study used part of the MACS data, which contained 2285 participants with a follow-up 
time of 2.5 years started from June 2015. The large sample size and repeated measures of 
e-cigarettes and NRT use makes it an ideal dataset for addressing the prevalence and risk 
factors of e-cigarettes and/or NRT using among HIV-infected individuals. The purpose of 
this study is to 1) provide a description of current usage of cigarettes, e-cigarettes and 
nicotine replacement therapy, and 2) identify factors that are related to initiation of e-
cigarettes smoking and NRT use among HIV-infected men and men at high risk of HIV 
infection in the US. 
Methods 
The Multicenter AIDS Cohort Study (MACS) is an ongoing multi-center prospective 
longitudinal study established in 1984 to describe the natural and treated histories of HIV 
infection in men high risk of HIV infection. A total of 6972 men were enrolled from four 
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centers (Baltimore/Washington DC, Chicago, Los Angeles, and Pittsburgh) in three 
recruitment waves (1984-85, n=4954; 1987-1991, n=668; 2001-03, n=1350). Demographic, 
clinical, laboratory testing, and behavioral data were collected at semi-annual visits. The 
study has been described in detail previously (Kaslow et al., 1987). 
 
Behavioral questions related to tobacco use, e-cigarette and NRT use were collected since 
2015 by primarily a separate self-administered web-based questionnaire, a computerized 
assisted direct interview (CADI) was used as a secondary option for administration. Overall, 
this study included all data after this time including 9877 person-visits contributed from 
2285 people. The study populations used in the prevalence description and risk factor 
analyses are shown in the flow chart (Figure 1). 
 
Outcomes 
 questions about e-cigarettes in each visit: “1) Since your last visit, have you smoked E-
cigarettes? 2) Are you smoking them now?” E-cigarette use for a visit was defines as 
answer “yes” or “occasionally” to either of the two questions. Ever e-cigarette users were 
those who reported using e-cigarettes for at least one visit. Never e-cigarette users were 
those who never reported using e-cigarettes in any of the visits.  
 
NRT using was defined as ever and never NRT using. There was one question about NRT 
usage: “Since your last visit, have you used any stop-smoking medications, such as patch, 
gum, nasal spray, inhalers, or lozenges?” NRT use for a visit was defines as answer “yes” 
or “occasionally” to the question. Ever NRT users were those who reported using NRT for 
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This study also included several independent variables in the risk factor analysis, including 
age, race, education level, HIV treatment, detectable viral load and CD4 count. These 
variables were included because previous studies had indicated that demographic, 
socioeconomic (Rutten et al., 2015), and health conditions (Pacek et al., 2016) might be 
related with e-cigarettes or NRT initiation.  
 
Age at each visit was calculated by date of birth and was treated as a continuous variable. 
Race was characterized using race and Hispanic ethnicity. We grouped American Indian, 
Alaskan Native, Asian, Pacific Islander and others together as “Other” because of the small 
numbers (n=159,7.0%).  Self-reported highest education level was collected at each visit 
and was categorized as high school or less, high school, some college and 4-year college 
and above.  
 
HIV seroconversion status was assessed by enzyme-linked immunosorbent assay with 
confirmatory Western blot tests on all HIV-seronegative participants at each visit and 
dichotomized as HIV-seropositive (men with HIV) and HIV-seronegative (men without 
HIV). CD4+ T-lymphocyte subset levels was measured by standardized flow cytometry at 
each visit and was grouped as below and above 350 cells/mm3. Self-reported use of highly 
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active antiretroviral therapy (HAART) was defined as yes or no at each visit. Detectable 
viral load was defined as <20 copied/ml (measured by TaqMan® HIV-1 Test) at each visit.  
 
Data analysis 
We first calculated the visit-specific prevalence of smoking as the number of current 
smokers over the total number of participants under follow up in each visit. To describe 
the use of e-cigarettes, we then calculated the prevalence of ever e-cigarettes use among 
current and former smokers by seroconversion status, as the number of e-cigarette users 
divided by the total number of current or former smokers for each visit. Confidence 
intervals for the prevalence above were also calculated and depicted. Then for the NRT 
use, similar prevalence was calculated using the total number of current and former 
smokers as the denominator. Confidence intervals for the prevalence were calculated and 
depicted as well. 
 
Univariate and multivariate Poisson regression models with robust variance were 
performed to identify risk factors for e-cigarettes use and cumulative incidence risk ratios 
(RR) were reported. Age, race, Hispanic ethnicity, education, HIV seroconversion status, 
HIV treatment, CD4 count, and cumulative pack-years were included in the univariate and 
the multivariate models. All the covariates were included for adjustment in the multivariate 
Poisson regression model. For the Poisson regression models, each person has one row of 
data. Risk factors were obtained from the visit when a man first reported using e-cigarettes 
or NRT, or from last visit for men who never reported using e-cigarettes or NRT. A 
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complete case analysis approach that excludes those with missing data for any of the risk 
factors was used. Analyses were conducted using STATA 14.0. 
Results 
Baseline demographic data for HIV-infected men and uninfected men are shown in Table 
1. There were 2285 participants included in our study. The number of HIV-infected and 
uninfected men were roughly similar (46.9% were men with HIV). The infected men were 
younger than uninfected men (median age=60.3 vs. 54.5). HIV-infected men were more 
likely to black (44.6% compared with 18.5%) and to have Hispanic ethnicity (15.4% 
compared to 8.0%). The education level was also higher for uninfected men, over 85% of 
them had more than high school education while only above 75% of uninfected men went 
beyond high schools. Nearly all of the infected men were receiving HAART treatment 
(above 96%) and most of them had a CD4 count more than 350 cells/mm
3 (93.4%). The 
prevalence of current smokers was higher among infected men (25.7%) compared with 
uninfected men (15.6%), but the prevalence of former smokers was slightly higher among 
HIV-infected men (52.3% compared with 44.6%). The prevalence of e-cigarettes use and 
NRT use both were higher among infected men (9.0% vs. 6.0% and 5.0% vs. 2.7%). 
 
The current smoking prevalence in the MACS (by HIV infection status) and the general 
US population of adult men in 2015 and 2016 is shown in Figure 2. The prevalence of 
current smokers in HIV-infected men is depicted by the blue dots and corresponding 95% 
confidence intervals, and uninfected men depicted by the red dots. Gray dots represent the 
prevalence of current smokers in US adult men for the corresponding year. The prevalence 
of current cigarette smoking among US adult men was 16.7% in 2015 and 17.5% in 2016 
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(Jamal, 2018; Phillips, 2017). The prevalence among men without HIV was 15.7% and 
16.1% for the two visits in 2015, respectively, and this was constant with the prevalence 
of US national adult men at 16.7%. The prevalence remained stable for year 2016 and 2017 
(15.8%, 13.5%, 16.1%), also constant with the US national prevalence. However, the 
prevalence of smoking was higher among infected men, at 26.1% and 24.1% for 2015. The 
prevalence ranged from 23.0% to 25.1% in 2016 and 2017.  
 
The prevalence of e-cigarettes smoking among all the participants is illustrated in Figure 
3. Blue dots are for prevalence of e-cigarettes smoking among HIV-infected men, red dots 
for uninfected men and gray dots for US adult men in 2015. Overall, the prevalence was 
higher during April to September in 2015 (9.3% and 5.7%, for infected and uninfected men, 
respectively), which is the first time this question was added into the behavioral 
questionnaire, then it decreased and remained stable (between 5.2% and 6.7% for infected 
men; and between 3.1 and 4.7% for uninfected men). Men with HIV had a slightly higher 
prevalence, but the difference was not significant. The prevalence in this study was slightly 
higher than the prevalence in US male adults (4.3%) (Phillips, 2017). Among the e-
cigarettes users, 73% were current smokers, 25% were former smokers, and 2% were never 
smokers.  
 
Among the current smokers, the prevalence of ever e-cigarettes use was higher than the 
prevalence in all participants and in former smokers. The prevalence was about 20% in 
current smokers, 4% in former smokers, and very few for non-smokers, at about 0.3%. The 
prevalence is shown in Figure 4a and Figure 4b below. Prevalence of e-cigarettes smoking 
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among HIV-infected men is in blue and uninfected men in red. A similar pattern of change 
was seen in current smokers, with a higher prevalence for the first visit during April to 
September in 2015 (28.1% for infected men and 27.7% for uninfected men), then stably 
ranged from 15.6% to 19.7% for infected men and from 11.6% to 20.1% for uninfected 
men. Among former smokers, the prevalence of e-cigarettes use was stable, ranging from 
2.7% to 3.8% for infected men, and from 2.0% to 2.6% for uninfected men. Again, the 
difference between infected and uninfected men were not significant.  
 
Figure 5 compares the current and former smokers’ cumulative pack-years (in the log scale) 
between ever e-cigarettes users vs. never e-cigarettes users. The median cumulative pack-
years were greater for e-cigarettes users than the non-users. The difference in median 
cumulative pack-years between e-cigarette users and non-users ranged from 1.3 to 8 pack-
years.  
 
The prevalence of NRT use among current and former smokers is shown in Figure 6. Blue 
dots are for prevalence of NRT use among HIV-infected men, and red dots for uninfected 
men. Overall, the prevalence of NRT use ranged between 5.0% and 8.2% for infected men 
and between 3.5% and 4.6% for uninfected men. Infected men had a slightly higher but not 
significant higher prevalence then uninfected men. The prevalence of NRT use was 
consistent across time. Among the NRT users, 70.7% were current smokers and 26.8% 
were former smokers and 2.6% were never smokers.  
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Among current smokers, the prevalence of NRT use was higher than in former smokers. 
The prevalence was about 12% in current smokers and about 3% in former smokers. Figure 
7a and 7b depict the prevalence and patterns. Prevalence of NRT use among HIV-infected 
men is in blue and uninfected men in red. For both current and former smokers, the 
prevalence did not change much during the study follow-up (Among current smokers: 
ranged from 10.6% to 17.3% for infected men; ranged from 9.2% to 12.9% for uninfected 
men. Among former smokers: ranged from 0.9% to 3.8% for infected men; ranged from 
1.1% to 2.2% for uninfected men). Men living with HIV had a slightly higher prevalence 
of NRT use compared to uninfected men, but this difference was not significant.  
 
Figure 8 shows the comparison of current and former smokers’ cumulative pack-years 
between ever NRT users and never NRT users. The median cumulative pack-years were 
greater for NRT users than the non-users. The difference in median cumulative pack-years 
between NRT users and non-users ranged from 13.7 to 20.6 pack-years. 
 
Table 2 summarizes the characteristics of ever e-cigarette users and never users and the 
potential risk factors. Among the 472 current smokers, 286 (60.1%) never reported using 
e-cigarettes and 186 (39.9%) ever reported using e-cigarettes during the follow-ups. Never 
e-cigarette users were older than ever users (median age= 55.1 vs. 49.4) and had higher 
education level. E-cigarette users had a higher proportion of less than high school education 
at 16.1%, compared to 11.0% for never e-cigarette users. They were similar in race, 
Hispanic ethnicity, seropositive proportion, detectable viral load, CD4 count and 
cumulative pack-year. After adjusting for age, race, Hispanic ethnicity, education level, 
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serostatus, detectable viral load, CD4 count and cumulative pack-years, the multivariate 
Poisson regression with robust variance showed that age, education level, HIV infection 
and cumulative pack years were significantly associated with initiation of e-cigarettes 
smoking. In the data, we observed a decrease in the cumulative incidence risk of initiating 
e-cigarettes smoking by 2% with one year increase in age (95% CI, 1%-3%). The 
cumulative incidence risk of initiating e-cigarette smoking increased by 46% for high 
school level men compared to men with 4 years’ college and above (95% CI, 1%-210%), 
and increased by 1.55 times for men less than high school level education compared to men 
with 4 years’ college and above (95% CI, 1.03- 2.35). Men with HIV have a 9% higher 
cumulative incidence risk than uninfected men (95% CI, 0.98-1.23). With 50% increase in 
cumulative pack-years, the cumulative incidence risk of e-cigarette use became 1.02 times 
greater (95% CI, 0.99-1.04). 
 
The characteristics of ever NRT users and never users among current and former smokers 
and the potential risk factors are in Table 3. Among the 1501 former and current smokers, 
1304 (86.9%) never reported using NRT and 197(13.1%) reported using NRT in at least 
one of the follow up visits. Never NRT users were older in age than ever users (median 
age=59.0 vs. 54.1). Ever users were more likely to be black (44.7% vs. 24.3%) but less 
Hispanic ethnicity (6.6% vs. 14.3%). Never users had a higher education level, with 78% 
more than high school level compared to 63% for ever users. The cumulative pack-years 
was significantly greater for those ever users (28.0 vs. 7.5). They were similar in 
seropositive proportion, detectable viral load, and CD4 count. After adjusting for age, race, 
Hispanic ethnicity, education level, serostatus, detectable viral load, CD4 count and 
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cumulative pack-years, the multivariate Poisson regression model with robust variance 
showed that age, black race, high school level education,  HIV infection and cumulative 
pack-years were significantly associated with initiation of NRT use. The cumulative 
incidence risk of using NRT decreased by 5% with one year increase in age (95% CI, 3%-
5%). Black men have a 32% higher cumulative incidence risk compared to white men (95% 
CI, 0%-73%). The cumulative incidence risk of NRT use increased by 48% for high school 
level men compared to men with 4 years’ college and above (95% CI, 2%-215%). HIV 
infected men have 1.31 times the cumulative incidence risk than uninfected men (95% CI, 
0.99-1.72). With 50% increase in cumulative pack-years, the cumulative incidence risk of 
NRT use was 1.13 times greater (95% CI, 1.09-1.16).  
Discussion 
This study reveals smoking behaviors and e-cigarettes and NRT use for men with high risk 
of HIV infection. Cigarettes smoking is more prevalent among HIV-infected men. E-
cigarettes and NRT use are more common among current smokers. Very few never-smoked 
e-cigarettes and NRT users were captured in this study. A younger age, lower education 
level, HIV infection and longer cumulative pack-years are observed to be associated with 
e-cigarettes and NRT initiation. Future programs or policies regarding e-cigarettes or NRT 
behaviors among men with high risk of HIV infection should target to sub-populations with 
younger age, lower education level, HIV infection and greater smoking intensity.  
 
The prevalence of current cigarette smoking among the uninfected men was similar to the 
prevalence in the US adult men, indicating that the uninfected men was a representative 
sample of smoking behaviors of the US adult men. Although the uninfected men in the 
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MACS study population was constructed mostly by men at high risk of HIV infection. The 
prevalence was higher among the infected men. The higher prevalence smoking might be 
explained by the higher prevalence of other risky behaviors including alcohol abuse and 
drug injection among HIV-seropositive men. 
 
The prevalence of e-cigarette smoking among uninfected men was similar to the prevalence 
in the US adult men. HIV-infected men had a higher prevalence of e-cigarette smoking 
than the uninfected men and the US adult men. The prevalence of e-cigarette smoking was 
highest among current smokers. There was nearly no e-cigarette user among non-smokers 
in this study. A previous study reported that there was a notable portion of adolescent e-
cigarettes users appeared to be never cigarette smokers, which means they started smoking 
with e-cigarettes instead of tradition cigarettes (Arrazola et al., 2015). However, we 
observed very few e-cigarette users among non-smokers here. This could be explained by 
the relative older population with an average age of more than 55 years at baseline in this 
study. Arrazola’s study also revealed that the pattern of e-cigarettes use prevalence among 
adolescents and adults differed (Arrazola et al., 2015). E-cigarettes were introduced into 
US only after 2007. So the results from this study may not reflect the patterns in younger 
population. E-cigarettes users had a greater cumulative pack-years compared to non-users. 
These data from the MACS demonstrated that heavy smokers, as determined by cumulative 
pack years, were more likely to use e-cigarettes. They may have done so as a substitute for 
cigarette smoking or as a method to quit smoking, although these data were not collected.   
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NRT use was most common among current and former smokers. This is constant with the 
fact that NRT is mostly used as a method to stop smoking. We also notice that there were 
nine person-visits contributing from 8 persons that reported non-smokers and NRT use. 
We examined their other visits’ data, the smoking status were constantly never smokers; 
seven of them reported NRT use only for one visits, and one person reported twice. It is 
highly possible to be a misclassification of NRT use. The analyses in this study were 
therefore performed only among current and former smokers. The prevalence of NRT use 
among infected and uninfected men were not significantly different in this study. The 
prevalence was higher among current smokers than former smokers. This concomitant use 
of NRT and cigarettes is worrisome since NRT products are not recommend to be used 
together with smoking or any other form of tobacco products. The results suggested that 
NRT users were more likely to be heavy smokers, as determined by cumulative pack years, 
than non-users. Also, NRT users had a longer cumulative pack years than the e-cigarette 
users. This makes sense since NRT are usually recommended to heavy smokers.  
 
The risk factors associated with ever e-cigarette use and ever NRT use were similar. 
 Having a younger age, a lower level of education, infected with HIV, and a longer 
cumulative pack-years were associated with both the use of e-cigarettes and NRT. Black 
race is associated with NRT use only. The association between longer cumulative pack 
years and NRT use is understandable and is constant with a previous study (Shiffman, 
2005). But Shiffman’s study also revealed risk factors to be older age and better education, 
which are different from this study. This difference could be explained by the difference in 
study populations. NRT users was defined only as NRT users who were current smokers 
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and had made a quit attempt in Shiffman’s study. While we included all e-cigarettes and 
NRT users regardless of quit attempt. Also, only men were included in this study while 
Shiffman’s study included both sexes. So the difference in risk factors might have 
something to do with their pattern of NRT use, that is, whether they were use NRT together 
with cigarettes or only NRT to quit smoking. The association between young age and 
increase use of NRT and e-cigarettes might be explained by the relatively older population 
we have. The e-cigarettes and NRT are nicotine products that are relatively new. Younger 
people are more likely to accept new things and are more willing to do something to 
improve their health. The association between HIV infection and e-cigarettes/NRT use 
could be explained by the fact that HIV infected men are usually on regular medication and 
insurance plan. They are expose to more health improving information and are more 
motivated to quit or reduce the amount of smoking to improve their health condition. Men 
with lower education level are more likely to use e-cigarettes or NRT. This is because 
people with a lower education level usually have very limited access to other stop smoking 
assistance, such as individual counselling. E-cigarettes and NRT seem to be more 
accessible and affordable to them. Another interesting finding is that men with high school 
and less than high school education were more likely to use e-cigarettes, compared to men 
with higher than college level education. But only high school level education was 
associated with NRT use. This could be explained by the price difference. NRT are much 
more expensive than e-cigarettes. Less than high school education may limit the income 
level and therefore made NRT not affordable.  
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One of the strengths of this study is that MACS is a well-designed and well-conducted 
cohort with comprehensive information collected. This study utilized data from MACS 
consisting 2285 individuals and 2.5 years of follow-up time. With MACS study population 
being a representative sample of the MSM population, it is reasonable to say this study 
provided a good profile of the e-cigarettes and NRT use behaviors for the MSM population.  
 
The limitations of this study are as follows: 1) There was no question about quit smoking 
attempts in the MACS questionnaires. We were therefore unable to address the association 
between e-cigarettes/NRT use and quit attempts. Although e-cigarettes users showed a 
higher smoking intensity than non-users, we were not able to identify whether they were 
using it as a substitute to cigarette smoking or as an assistance to quit smoking.  2) 
Questions regarding e-cigarettes and NRT use were added since 2015. There were only 5 
visits afterwards, which leaves our follow-up time at 2.5 years. With such a short term 
follow-up, it is unlikely to capture any trend change in the prevalence of e-cigarettes and 
NRT use. 3) The risk factors included in this study is not a complete list of all possible 
factors due to the limitation of information collected. E-cigarettes and NRT are more 
expensive than traditional cigarettes so we think smokers’ socioeconomic status and 
insurance plan might affect their behavior as well. Including more variables regarding 
socioeconomic status and insurance plan might be better than education level alone.  
Conclusion 
The prevalence of current smoking was higher for HIV-infected men than uninfected 
men. E-cigarettes and NRT use was mostly common among current smokers, the 
prevalence does not differ by HIV status. E-cigarettes and NRT users had a longer 
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cumulative pack-years compared to never users. Risk factors associated with both e-
cigarettes and NRT use included younger age, lower education level, HIV infection and 
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Tables and figures 
 
 
Table 1. Baseline characteristics (HIV-infected vs. uninfected men) (N=2285) 
 Uninfected Infected p-value 
Total 1072 1213  
Age (median, IQR) 60.3 (53.2, 67.0) 54.5 (46.0, 61.1) <0.001 
Race   <0.001 
     White   822 (76.7%) 738 (60.9%)  
     Black 198 (18.5%) 366 (44.6%)  
     Other a 52 (4.9%) 107 (8.8%)  
Hispanic ethnicity 86 (8.0%) 187 (15.4%) <0.001 
Education level   <0.001 
     4 years’ college and above 655 (61.1%) 545 (44.9%)  
     Some college 263 (24.5%) 378 (31.2%)  
     High school (12th grade) 117 (10.9%) 204 (16.8%)  
     Less than high school 37 (3.5%) 86 (7.1%)  
On HAART NA 1176 (96.9%)  
CD4 < 350 cells/mm
3 NA 92 (7.6%)  
Smoking status   <0.001 
     Never smoked 330 (32.0%) 354 (29.6%)  
     Former smoker 539 (52.3%) 532 (44.6%)  
     Current smoker 161 (15.6%) 306 (25.7%)  
Ever used e-cigarettes since last visit 60 (6.0%) 103 (9.0%) 0.009 
Used NRT since last visit 27 (2.7%) 57 (5.0%) 0.007 
a American Indian, Alaskan Native, Asian, Pacific Islander, and others 
Figure 1. Flow chart showing study populations in each analysis step. 
 
 
Figure 2. Prevalence of current smokers in MACS by visit, by serostatus 
 
 
Figure 3. Prevalence of ever e-cigarettes users in MACS by visit, by serostatus 
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Figure 4a-b. Prevalence of ever E-cigarettes users among current smokers (left) and 
former smokers (right)in MACS by visit, by serostatus 
 
 
Figure 5. Cumulative pack-years among E-cigarettes users and non-users who are current 





Figure 6. Prevalence of NRT use among current and former smokers in MACS by visit, 
by serostatus 
 
Figure 7a-b. Prevalence of NRT use among current smokers (left) and former smokers 












Figure 8. Cumulative pack-years among NRT users and non-users who are current or 







Table 2. Descriptive statistics of characteristics of E-cigarette users vs. non-users, among current smokers and their association with ever e-







incidence risk ratio (RR) 
(95% CI) 
Multivariateb cumulative 
incidence risk ratio (RR) 
(95% CI) 
Total 282 186   
Age (median, IQR) 55.1 (45.9, 61.0) 49.4 (39.4, 56.0) 0.98**(0.97, 0.99) 0.98** (0.97, 0.99) 
Race     
     White   121 (43.1%) 82 (44.1%) ref ref 
     Black 141 (50.2%) 92 (49.5%) 0.98 (0.73, 1.32) 0.82 (0.64, 1.05) 
     Other a 19 (6.8%) 12 (6.5%) 0.96 (0.52, 1.76) 0.66(0.34, 1.27) 
Hispanic ethnicity 26 (9.2%) 22 (11.8%) 1.17 (0.75, 1.83) 1.10 (0.71, 1.71) 
Education level     
     4 years’ college and above 94 (33.3%) 37 (19.9%) ref ref 
     Some college 95 (33.7%) 67 (36.0%) 1.46 (0.98, 2.19) 1.26 (0.90, 1.76) 
     High school (12th grade) 62 (22.0%) 52 (28.0%) 1.61* (1.06, 2.46) 1.46* (1.01, 2.10) 
     Less than high school 31 (11.0%) 30 (16.1%) 1.74* (1.08, 2.82) 1.55* (1.03, 2.35) 
Seropositive 177 (62.8%) 126 (67.7%) 1.14 (0.84, 1.55) 1.09 (0.98, 1.23) 
Detectable viral load c 177 (62.8%) 126 (67.7%) 0.80 (0.53, 1.21) 0.79 (0.50, 1.26) 
Current CD4 < 350 cells/mm
3 c 16 (5.7%) 10 (5.4%) 1.00 (0.53, 1.91) 1.07 (0.54, 2.14) 
Cumulative pack-years, median (IQR) 19.9 (7.6, 41.5) 20.1 (6.8, 36.7) 0.99d (0.97, 1.01) 1.02d (0.99, 1.04) 
a American Indian, Alaskan Native, Asian, Pacific Islander, and others 
b Adjusted for age, race, Hispanic ethnicity, education level, serostatus, detectable viral load, CD4 count and cumulative pack-years 
c Restricted to men with HIV-infection, additionally adjust for detectable viral load and low CD4 count 





Table 3. Descriptive statistics of characteristics of NRT users vs. non-users, among current and former smokers and their association with ever 




Ever NRT users 
Univariate cumulative 
incidence risk ratio(RR)  
(95% CI) 
Multivariateb cumulative 
incidence risk ratio(RR) 
(95% CI) 
Total 1304 197   
Age (median, IQR) 59.0 (50.7, 66.0) 54.1 (47.2, 59.4) 0.98**(0.97, 0.99) 0.95** (0.95, 0.97) 
Race     
     White   884 (67.8%) 103 (52.3%) ref ref 
     Black 317 (24.3%) 88 (44.7%) 2.08** (1.57, 2.77) 1.32* (1.00, 1.73) 
     Other a 102 (7.8%) 6 (3.0%) 0.53 (0.23, 1.21) 0.59 (0.25, 1.36) 
Hispanic ethnicity 186 (14.3%) 13 (6.6%) 0.46** (0.26, 0.81) 0.71 (0.38, 1.30) 
Education level     
     4 years’ college and above 642 (49.2%) 54 (27.4%) ref ref 
     Some college 381 (29.2%) 70 (35.5%) 2.00** (1.40, 2.85) 1.36 (0.97, 1.91) 
     High school (12th grade) 203 (15.6%) 51 (25.9%) 2.59** (1.77, 3.79) 1.48* (1.02, 2.15) 
     Less than high school 78 (6.0%) 22 (11.2%) 2.84** (1.73, 4.66) 1.36 (0.85, 2.16) 
Seropositive 693 (53.1%) 132 (67.0%) 1.66** (1.24, 2.24) 1.31 (0.99, 1.72) 
Detectable viral load c 99 (30.1%) 24 (24.0%) 0.80 (0.51, 1.27) 0.72 (0.44, 1.16) 
Current CD4 < 350 cells/mm
3 c 61 (4.7%) 11 (5.6%) 1.08 (0.58, 2.00) 1.19 (0.61, 2.34) 
Cumulative pack-years, median 
(IQR) 
7.5 (0.3, 26.3) 28.0 (11.8, 48.2) 1.07**d (1.04, 1.09) 1.10**d (1.07, 1.14) 
a American Indian, Alaskan Native, Asian, Pacific Islander, and others 
b Adjusted for age, race, Hispanic ethnicity, education level, serostatus, detectable viral load, CD4 count and cumulative pack-years 
c Restricted to men with HIV-infection, additionally adjust for detectable viral load and low CD4 count 








Xuechen Li, ScM, BS 
11/07/1992 Baoding, China 
 
2011-2016 Bachelor of Medicine in Preventive Medicine  
Peking University Health Science Center, School of Public Health (Beijing, China) 
2011-2016 Bachelor of Science in Psychology 
Peking University, Department of Psychology (Beijing, China) 
2016-2018 Master of Science in General Epidemiology and Methodology   
Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA) 
 
